Profile data is unavailable for this security.
About the company
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
- Revenue in USD (TTM)0.00
- Net income in USD-32.14m
- Incorporated2007
- Employees11.00
- LocationForte Biosciences Inc3060 PEGASUS PARK DRIVE, BUILDING 6DALLAS 75247United StatesUSA
- Phone+1 (310) 618-6994
- Fax+1 (302) 655-5049
- Websitehttps://www.fortebiorx.com/home/default.aspx
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trinity Biotech plc (ADR) | 56.71m | -33.88m | 19.88m | 380.00 | -- | -- | -- | 0.3505 | -4.42 | -2.81 | 7.41 | -14.96 | 0.625 | 1.69 | 3.67 | 149,229.00 | -37.34 | -20.30 | -47.55 | -29.54 | 34.21 | 39.92 | -59.75 | -29.86 | 1.03 | -1.96 | 1.36 | -- | -9.10 | -10.15 | 15.41 | -- | -31.08 | -- |
| Allied Corp | 21.51k | -9.00m | 20.11m | -- | -- | -- | -- | 934.69 | -0.0915 | -0.0915 | 0.0002 | -0.0711 | 0.0051 | 1.65 | 0.1441 | -- | -214.39 | -- | -- | -- | -6,919.57 | -- | -41,861.41 | -- | 0.0333 | -31.86 | -- | -- | -56.46 | -- | 31.30 | -- | -- | -- |
| Lumos Pharma Inc | 1.53m | -37.13m | 20.13m | 33.00 | -- | 1.15 | -- | 13.20 | -4.59 | -4.59 | 0.1886 | 2.15 | 0.0332 | -- | 8.01 | 46,212.12 | -80.89 | -29.78 | -90.15 | -32.32 | -- | -- | -2,434.69 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Bullfrog AI Holdings, Inc. | 65.00k | -5.95m | 20.65m | 4.00 | -- | 3.03 | -- | 317.65 | -0.8903 | -0.8903 | 0.0097 | 0.8667 | 0.0094 | -- | -- | 16,250.00 | -85.49 | -- | -103.85 | -- | 92.00 | -- | -9,129.42 | -- | -- | -278.20 | 0.0694 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
| Ibio Inc | 50.00k | -17.13m | 20.87m | 26.00 | -- | 0.829 | -- | 417.39 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
| Polypid Ltd | 0.00 | -24.25m | 20.92m | 59.00 | -- | 2.93 | -- | -- | -12.35 | -12.35 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -84.94 | -76.92 | -120.03 | -89.61 | -- | -- | -- | -- | -- | -28.72 | 0.5498 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Vincerx Pharma Inc | 0.00 | -38.25m | 21.03m | 42.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.029 | 0.00 | -- | -- | 0.00 | -130.68 | -- | -205.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 36.24 | -- | -- | -- |
| Zivo Bioscience Inc | 63.37k | -7.08m | 21.15m | 8.00 | -- | -- | -- | 333.83 | -3.83 | -3.83 | 0.0318 | -0.8133 | 0.0652 | -- | -- | 7,921.25 | -728.52 | -376.60 | -- | -- | 38.05 | -- | -11,176.47 | -96,315.32 | -- | -88.46 | -- | -- | -- | -- | 11.07 | -- | -- | -- |
| Forte Biosciences Inc | 0.00 | -32.14m | 21.25m | 11.00 | -- | 0.7398 | -- | -- | -1.03 | -1.03 | 0.00 | 0.7882 | 0.00 | -- | -- | 0.00 | -93.54 | -72.06 | -104.30 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Bioxytran Inc | 0.00 | -4.30m | 21.26m | 2.00 | -- | -- | -- | -- | -0.0297 | -0.0297 | 0.00 | -0.0017 | 0.00 | -- | -- | -- | -2,431.80 | -1,420.53 | -- | -- | -- | -- | -- | -- | -- | -7.69 | -- | -- | -- | -- | -73.71 | -- | -- | -- |
| Nanopharmaceutics Inc | 1.01m | -549.47k | 22.33m | 50.00 | -- | -- | -- | 22.12 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -31.60m | 22.52m | 9.00 | -- | -- | -- | -- | -4.48 | -4.48 | 0.00 | -5.23 | 0.00 | -- | -- | 0.00 | -61.90 | -49.89 | -65.32 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 22.54m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Indaptus Therapeutics Inc | 0.00 | -14.98m | 22.63m | 7.00 | -- | 2.42 | -- | -- | -1.78 | -1.78 | 0.00 | 1.10 | 0.00 | -- | -- | 0.00 | -87.86 | -66.55 | -97.46 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
Data as of Jun 11 2024. Currency figures normalised to Forte Biosciences Inc's reporting currency: US Dollar USD
54.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tybourne Capital Management (HK) Ltd.as of 31 Mar 2024 | 3.62m | 9.96% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 3.27m | 8.97% |
| BVF Partners LPas of 31 Mar 2024 | 2.98m | 8.19% |
| Cable Car Capital LLCas of 31 Mar 2024 | 2.03m | 5.58% |
| Fred Alger Management LLCas of 31 Mar 2024 | 1.84m | 5.05% |
| Farallon Capital Management LLCas of 31 Mar 2024 | 1.81m | 4.97% |
| BML Capital Management LLCas of 31 Mar 2024 | 1.76m | 4.84% |
| Camac Partners LLCas of 03 Jan 2024 | 1.58m | 4.33% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 642.26k | 1.77% |
| Geode Capital Management LLCas of 31 Mar 2024 | 343.43k | 0.94% |
More ▼
Data from 31 Mar 2024 - 29 May 2024Source: FactSet Research Systems Inc.
